Kinfo
Translational Development Acquisition Corp. logo

Translational Development Acquisition Corp.

TDACNASDAQFinancial Services·US · USD
$10.69
-0.03 (-0.28%)
Close · 2026-06-26

Price

Key statistics

Valuation
Market cap206.41M USD
Enterprise value234.67M USD
Trailing P/E38.18
Forward P/E378.50
PEG ratio-2.67
Price / sales0.00
Price / book1.33
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-0.31%
Return on equity3.63%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income6.21M USD
Diluted EPS$0.28
Rev. growth (YoY)0.00%
Balance sheet
Total cash24.63K USD
Total debt500.00K USD
Debt / equity0.00
Current ratio0.09
Book value / share-$0.31
Cash flow (TTM)
Operating cash flow-681.97K USD
Levered free cash flow-352.61K USD
Shares & price
Shares outstanding21.91M
Float14.70M
Held by institutions79.72%
Beta0.00
50-day MA$10.69
200-day MA$10.53
52-week high$10.80
52-week low$10.27
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-272.912.90−0.34%2026-05-15-0.53-0.61−15.09%2026-05-040.780.87+11.54%2026-04-241.561.59+1.92%2026-03-30-0.65-0.68−4.62%
About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with businesses in the biopharmaceutical and pharmaceutical industry sectors. Aiming to leverage and support the growth of novel life sciences enterprises, this SPAC is dedicated to facilitating strategic partnerships that can lead to innovation and advancement in drug development and healthcare solutions. Translational Development Acquisition Corp. primarily targets companies with promising research and development pipelines that have the potential to transform patient care and enhance therapeutic options. This acquisition entity plays a pivotal role in providing capital and market access for rising enterprises within the dynamic and evolving field of biotechnology and pharmaceuticals, emphasizing the importance of scientific progress and industry collaboration in addressing unmet medical needs.

Sector
Financial Services
Industry
Shell Companies
CEO
Mr. Michael M. B. Hoffman J.D.
Headquarters
New York, NY, United States

Frequently asked questions about Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) Stock Price, Statistics & Dividends | Kinfo